A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer.
Yoshioka H, Katakami N, Okamoto H, Iwamoto Y, Seto T, Takahashi T, Sunaga N, Kudoh S, Chikamori K, Harada M, Tanaka H, Saito H, Saka H, Takeda K, Nogami N, Masuda N, Harada T, Kitagawa H, Horio H, Yamanaka T, Fukuoka M, Yamamoto N, Nakagawa K.
Yoshioka H, et al. Among authors: harada m, harada t.
Ann Oncol. 2017 Feb 1;28(2):285-291. doi: 10.1093/annonc/mdw621.
Ann Oncol. 2017.
PMID: 28426104
Free article.
Clinical Trial.